ENTITY
Sinomab Bioscience Ltd

Sinomab Bioscience Ltd (3681 HK)

12
Analysis
Health CareHong Kong
Sinomab Bioscience Limited manufactures antibody drugs. The Company researches, develops, and manufactures anti-infective drugs, antitumor agents, and monoclonal antibodies. Sinomab Bioscience markets its products worldwide.
more
Refresh
04 Mar 2020 13:24

InnoCare (诺诚健华) Pre-IPO: PHIP and Valuation Update

InnoCare Pharma Limited is a clinical-stage biopharmaceutical company with a focus on small molecule inhibitors for BTK, and FGFRs. The company...

Logo
473 Views
Share
28 Jan 2020 12:49

InnoCare (诺诚健华) Pre-IPO: Thoughts on Valuation

InnoCare Pharma Limited is a clinical-stage biopharmaceutical company with a focus on small molecule inhibitors for BTK, and FGFRs. The company...

Logo
469 Views
Share
15 Jan 2020 10:06

Aequitas 2019 IPOs and Placements Performance - Things We Got Right/Wrong and Things We Plan to Do

2019 marked our first full year of operations as an Independent Research Company, post spin-off from Smartkarma in August 2018. With our...

Logo
571 Views
Share
12 Nov 2019 11:05

SinoMab (中国抗体) Post-IPO Trading: Decent Retail Interests Can't Save the Day

SinoMab's IPO was priced at the low end and started trading today. We have highlighted in our earlier note that 1) the company's core product...

Logo
344 Views
Share
bullishTyro Payments
09 Nov 2019 12:56

ECM Weekly (9 Nov 2019) - Phoenix Tree, I-Mab, Tyro Payments, Pharmaron, Heaven-Sent

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Hong Kong...

Share
x